Both patients with IPF and patients with PPF treated with nerandomilast demonstrated a smaller decline in forced vital capacity over 52 weeks versus placebo.
The post Nerandomilast Slows IPF & PPF Lung Function Decline: FIBRONEER first appeared on Physician’s Weekly.
